Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research GroupFootnote

* Preliminary data from this study have been presented at the 52nd conference of the American Society of Hematology in San Francisco, December 2014.

*

References

• Thyss A, Saada E, Gastaud L, et al. Hodgkin's lymphoma in older patients. An orphan disease? Mediterr J Hematol Infect Dis. 2014;6:e2014050.
   PubMedGoogle Scholar
• Proctor SJ, Wilkinson J, Sieniawski M. Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol. 2009;71:222–232.
   PubMed Web of Science ®Google Scholar
• Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;119:990–996.
   PubMed Web of Science ®Google Scholar
• Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012;119:692–695.
   PubMed Web of Science ®Google Scholar
• Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23:5052–5060.
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119:6005–6015.
   PubMed Web of Science ®Google Scholar
• Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol. 2004;15:123–128.
   PubMed Web of Science ®Google Scholar
• Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005;16:124–131.
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88:438–444.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii70–iii75.
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Rueffer JU, Angus B, et al. Hodgkin's disease in the elderly: current status and future directions. Ann Oncol. 2002;13:133–137.
   PubMed Web of Science ®Google Scholar
• Halbsguth TV, Nogova L, Mueller H, et al. Phase II study of BACOPP (Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116:2026–2032.
   PubMed Web of Science ®Google Scholar
• Boell B, Bredenfeld H, Goergen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118:6292–6298.
   PubMed Web of Science ®Google Scholar
• Zallio F, Tamiazzo S, Monagheddu C, et al. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL. ). Br J Haematol. 2016;172:879–888.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. J Clin Oncol. 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Ann Stat. 1982;10:1100–1120.
   Web of Science ®Google Scholar
• Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526.
   Web of Science ®Google Scholar
• Śliwczyński A, Tkacz A, Charliński G, et al. Incidence and morbidity for Hodgkin’s lymphoma in Poland evaluated on the basis of data from the Polish National Health Insurer for the years 2004–2010. Nowotw J Oncol. 2012;62:175–183.
   Google Scholar
• Didkowska J, Wojciechowska U, Olasek P, et al. Cancer in Poland 2015. Warsaw: Ministry of Health. 2017;49. Availabl from: http://onkologia.org.pl/wp-content/uploads/Nowotwory_2015.pdf.
   Google Scholar
• Erdkamp FL, Breed WP, Bosch LJ, et al. Hodgkin disease in the elderly. A registry-based analysis. Cancer. 1992;70:830–834.
   PubMed Web of Science ®Google Scholar
• Life expectancy in Poland 1950–2016. Secondary Life expectancy in Poland 1950-2016; 2016. [cited 2018 April 30]. Available from: https://stat.gov.pl/en/topics/population/life-exp-ectancy/life-expectancy-in-poland,1,3.html.
   Google Scholar
• Mir R, Anderson J, Strauchen J, et al. Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease: the Cancer and Leukemia Group B. Cancer. 1993;71:1857–1866.
   PubMed Web of Science ®Google Scholar
• Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31:1522–1529.
   PubMed Web of Science ®Google Scholar
• Walewski J, Lampka E, Tajer J, et al. CHOP-21 for unfavorable Hodgkin's lymphoma. An exploratory study. Med Oncol. 2010;27:262–267.
   PubMed Web of Science ®Google Scholar
• Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's Lymphoma. N Engl J Med. 2016;374:2419–2429.
   PubMed Web of Science ®Google Scholar
• Trotman J, Fosså A, Federico M, et al. Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after a negative interim pet scan (CRUK/07/033). Hematol Oncol. 2017;35:65–67.
   Google Scholar
• Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma. 2007;48:570–576.
   PubMed Web of Science ®Google Scholar
• Macpherson N, Klasa RJ, Gascoyne R, et al. Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma. 2002;43:1395–1402.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Szmit S, Sobociński M, et al. Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen – a national multicenter study. Int J Cardiol. 2013;168:5212–5217.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Bijou F, Viotti J, et al. Brentuximab‐vedotin and bendamustine is a feasible and effective drug combination as first‐line treatment of Hodgkin lymphoma in the elderly (halo trial). Hematol Oncol. 2017;35:170–170.
   Google Scholar
• Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017;130:2829–2837.
   PubMed Web of Science ®Google Scholar